v3.24.1.1.u2
BASIS OF FINANCIAL STATEMENT PREPARATION (Details)
$ in Millions
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
segment
country
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Concentration Risk [Line Items]                
Number of reportable segments | segment 1              
Number of operating segments | segment 1              
Number of countries with primary office locations | country 5              
Selling, general and administrative expenses, exclusive of depreciation and amortization $ 120.1 $ 106.8 $ 97.8 $ 116.8 $ 214.6 $ 321.4 $ 448.1 $ 416.1
Decrease of direct costs $ (554.2) $ (563.8) $ (568.7) (541.5) $ (1,110.2) $ (1,674.0) $ (2,251.9) $ (2,112.6)
Interest income (expense)       0.1        
Reclassifications                
Concentration Risk [Line Items]                
Selling, general and administrative expenses, exclusive of depreciation and amortization       45.3        
Decrease of direct costs       $ 45.3        
Customer one | Accounts receivable and unbilled services | Customer concentration risk                
Concentration Risk [Line Items]                
Concentration risk, percentage 19.30%              
Customer one | Revenue | Customer concentration risk                
Concentration Risk [Line Items]                
Concentration risk, percentage 14.00%     10.00%        
Customer two | Accounts receivable and unbilled services | Customer concentration risk                
Concentration Risk [Line Items]                
Concentration risk, percentage 11.00%              
Customer two | Revenue | Customer concentration risk                
Concentration Risk [Line Items]                
Concentration risk, percentage 13.00%              
Pharmaceutical company one | Accounts receivable and unbilled services | Customer concentration risk                
Concentration Risk [Line Items]                
Concentration risk, percentage             17.00%  
Pharmaceutical company two | Accounts receivable and unbilled services | Customer concentration risk                
Concentration Risk [Line Items]                
Concentration risk, percentage             11.20%